within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FA03_Obinutuzumab;

model Obinutuzumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.5e-08,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.0038,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0031,
    k12 = 1.4444444444444445e-07,
    k21 = 1.4444444444444445e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Obinutuzumab</td></tr><tr><td>ATC code:</td><td>L01FA03</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.09</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Obinutuzumab is a glycoengineered humanized type II anti-CD20 monoclonal antibody used primarily in the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma. It acts by targeting the CD20 antigen on B lymphocytes, resulting in cell lysis. Obinutuzumab is approved for clinical use in various countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with relapsed or refractory CD20-positive B-cell malignancies following intravenous administration.</p><h4>References</h4><ol><li><p>Zhai, J, et al., &amp; Shi, J (2017). Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas. <i>British journal of clinical pharmacology</i> 83(7) 1446–1456. DOI:<a href=\"https://doi.org/10.1111/bcp.13232\">10.1111/bcp.13232</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28072473/\">https://pubmed.ncbi.nlm.nih.gov/28072473</a></p></li><li><p>Hoy, SM (2015). Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia. <i>Drugs</i> 75(3) 285–296. DOI:<a href=\"https://doi.org/10.1007/s40265-014-0340-3\">10.1007/s40265-014-0340-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25586272/\">https://pubmed.ncbi.nlm.nih.gov/25586272</a></p></li><li><p>Qin, Y, et al., &amp; Shi, Y (2018). Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial. <i>Cancer communications (London, England)</i> 38(1) 31–None. DOI:<a href=\"https://doi.org/10.1186/s40880-018-0300-5\">10.1186/s40880-018-0300-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29843792/\">https://pubmed.ncbi.nlm.nih.gov/29843792</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01FA03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Obinutuzumab;
